News

Corporate Responses re: Impact of COVID-19 Pandemic on Rare Disease Patients in Canada

To address concerns that we have been hearing from our members, CORD sent out a questionnaire to our corporate partners to learn how COVID-19 could affect their company’s support for rare disease patients in Canada, including supply of drugs for rare diseases and status of current or planned rare disease clinical trials. In addition, we queried about any potential increased risk of contracting COVID-19 or complications related to medications provided by their company. We appreciate the prompt response from these corporations, as listed below. We will update the list as we receive more information

Response:
Alexion
AstraZeneca
Bayer
Boehringer Ingelheim
GlaxoSmithKline
Horizon
Ipsen
Novartis
Pfizer

Janssen Canada Access and Affordability Support for Patients through the unprecedented challenge of COVID-19. Please click on their statement for more details.